Flop of new medication costs Novartis dearly
The pharmaceutical company has to write off almost two billion dollars because a potential new drug did not show the desired effect. The company's CEO is downplaying the failure. However, many market observers are skeptical.
We haven't written up this one. NZZ Wirtschaft has the full story — the link below goes straight to it.